Patents by Inventor Douglas E. Brenneman
Douglas E. Brenneman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220257620Abstract: The invention relates to compositions containing certain phosphatidylcholines containing long chain polyunsaturated fatty acids in the sn-1 position or both the sn-1 and sn-2 positions as a neuroprotective agent, and further to treating or preventing oxidative stress in a neuronal tissue with such compositions.Type: ApplicationFiled: June 26, 2020Publication date: August 18, 2022Inventors: Douglas E. BRENNEMAN, William A. KINNEY, Jason CLEMENT, Dean PETKANAS
-
Patent number: 10004722Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.Type: GrantFiled: February 20, 2017Date of Patent: June 26, 2018Assignee: KANNALIFE SCIENCES, INC.Inventors: Douglas E. Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
-
Publication number: 20170157097Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.Type: ApplicationFiled: February 20, 2017Publication date: June 8, 2017Inventors: Douglas E. BRENNEMAN, William Alvin KINNEY, Mark MCDONNELL, Dean PETKANAS
-
Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy
Patent number: 9611213Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.Type: GrantFiled: January 9, 2015Date of Patent: April 4, 2017Assignee: KANNALIFE SCIENCES, INC.Inventors: Douglas E Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas -
Publication number: 20160311769Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.Type: ApplicationFiled: January 9, 2015Publication date: October 27, 2016Inventors: Douglas E Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
-
Patent number: 8609849Abstract: Pharmaceutical compositions of the invention include hydroxylated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.Type: GrantFiled: November 29, 2011Date of Patent: December 17, 2013Assignees: Fox Chase Chemical Diversity Center, Inc., Advanced Neural Dynamics, Inc.Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
-
Publication number: 20130253022Abstract: Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity.Type: ApplicationFiled: November 18, 2011Publication date: September 26, 2013Applicants: FOX CHASE CHEMICAL DIVERSITY CENTER, INC., ADVANCED NEURAL DYNAMICS, INC.Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
-
Patent number: 7863247Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 10, 2000Date of Patent: January 4, 2011Assignee: Ramot-University Authority for Applied Research and Development Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20090247457Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.Type: ApplicationFiled: August 25, 2008Publication date: October 1, 2009Applicants: SECRETARY OF THE DEPTARTMENT OF HEALTH AND HUMAN SERVICES, RAMOT AT TEL-AVIV UNIVERSITYInventors: DOUGLAS E. BRENNEMAN, RAQUEL CASTELLON, CATHERINE Y. SPONG, JANET M. HAUSER, IIIANA GOZES
-
Publication number: 20090124543Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: ApplicationFiled: August 13, 2007Publication date: May 14, 2009Applicants: The Govt. of the U.S.A., as represented by the Secretary of the Dept. of Health & Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 7427590Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.Type: GrantFiled: September 12, 2002Date of Patent: September 23, 2008Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.Inventors: Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser, Illana Gozes
-
Publication number: 20080194488Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: ApplicationFiled: April 14, 2008Publication date: August 14, 2008Applicants: National Institute of Health, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Albert Pinhasov, Eliezer Giladi, Douglas E. Brenneman, Catherine Y. Spong
-
Patent number: 7384908Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: GrantFiled: August 17, 2000Date of Patent: June 10, 2008Assignee: National Institute of HealthInventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Albert Pinhasov, Eliezer Giladi
-
Patent number: 7264947Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: GrantFiled: July 17, 2003Date of Patent: September 4, 2007Assignee: United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 6933277Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 12, 1999Date of Patent: August 23, 2005Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20040235747Abstract: The present invention provides methods for preventing and/or treating autoimmune diseases, including multiple sclerosis, in a subject using ADNF polypeptides, by treating the subject with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide.Type: ApplicationFiled: December 29, 2003Publication date: November 25, 2004Applicants: Ramot At Tel-Aviv University Ltd., The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Illana Gozes, Daniel Offen, Eliezer Giladi, Eldad Melamed, Douglas E. Brenneman
-
Publication number: 20040053313Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: ApplicationFiled: July 17, 2003Publication date: March 18, 2004Applicants: The Government of the USA as Represented by the Secretary of the Dept. of Health & Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 6649411Abstract: The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.Type: GrantFiled: July 30, 1999Date of Patent: November 18, 2003Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Rachel Zamostiano, Edgar Gelber, Albert Pinhasov, Merav Bassan
-
Patent number: 6613740Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: GrantFiled: November 6, 1998Date of Patent: September 2, 2003Assignees: Ramot University Authority for Applied Research and Industrial Development Ltd., The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Publication number: 20030036521Abstract: The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.Type: ApplicationFiled: July 30, 1999Publication date: February 20, 2003Inventors: ILLANA GOZES, DOUGLAS E. BRENNEMAN, RACHEL ZAMOSTIANO, EDGAR GELBER, ALBERT PINHASOV, MERAV BASSAN